Tema Etfs LLC Boosts Stock Position in Amgen Inc. $AMGN

Tema Etfs LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 12.1% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 20,132 shares of the medical research company’s stock after purchasing an additional 2,168 shares during the period. Tema Etfs LLC’s holdings in Amgen were worth $6,589,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Board of the Pension Protection Fund purchased a new stake in shares of Amgen in the fourth quarter worth about $26,000. Olistico Wealth LLC acquired a new stake in Amgen in the 4th quarter valued at $33,000. Holos Integrated Wealth LLC purchased a new stake in shares of Amgen during the fourth quarter worth about $37,000. Howard Hughes Medical Institute purchased a new stake in Amgen during the 2nd quarter worth approximately $32,000. Finally, Cloud Capital Management LLC purchased a new stake in shares of Amgen during the third quarter worth approximately $34,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN stock opened at $353.28 on Thursday. The firm has a 50 day moving average of $363.57 and a two-hundred day moving average of $331.74. The stock has a market capitalization of $190.44 billion, a PE ratio of 24.83, a P/E/G ratio of 3.49 and a beta of 0.47. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s dividend payout ratio is currently 70.84%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst/sector endorsements: recent analyst commentary (Zacks) highlights Amgen’s strong drug portfolio and resilience versus sector headwinds, which supports investor sentiment and helps the stock. The Zacks Analyst Blog Roche Holding, AT&T and Amgen
• Positive Sentiment: Inclusion in buy lists: Amgen appears in a recent “5 Best Pharma Stocks to Invest In Now” roundup, which can attract longer‑term inflows and positive sentiment from retail/institutional investors. 5 Best Pharma Stocks to Invest In Now
• Neutral Sentiment: Brokerage consensus: a recent survey shows AMGN carries an average “Hold” rating from brokerages — not a downgrade but a sign analysts see limited near‑term upside absent new catalysts. Amgen Inc. (NASDAQ:AMGN) Given Average Rating of “Hold” by Brokerages
• Negative Sentiment: Safety alert on Tavneos: the U.S. FDA has flagged multiple cases of drug‑induced liver injury — including deaths — linked to Amgen’s rare‑disease drug Tavneos (76 cases identified). The agency is urging closer monitoring and prompt discontinuation if liver damage is suspected; this poses regulatory, reputational and potential liability risks that could pressure the stock. US FDA warns of liver injury cases tied to Amgen’s rare disease drug FDA Says Amgen’s Tavneos Linked to Liver Injuries, Deaths
• Negative Sentiment: Biosimilars competition: Teva won FDA approval for a Prolia biosimilar (Ponlimsi) and advanced other biosimilar filings — increased biosimilars activity raises competitive pressure in areas where Amgen has legacy biologics, potentially weighing on future sales. TEVA’s Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted

Wall Street Analyst Weigh In

Several analysts recently issued reports on AMGN shares. The Goldman Sachs Group upped their price objective on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. Mizuho raised their price objective on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Jefferies Financial Group began coverage on Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price on the stock. Rothschild & Co Redburn upped their price target on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research note on Wednesday, February 18th. Finally, BMO Capital Markets raised their price target on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $354.60.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.